← Back to Screener
GH Research PLC Ordinary Shares (GHRS)
Price$21.50
Favorite Metrics
Price vs S&P 500 (26W)36.92%
Price vs S&P 500 (4W)21.79%
Market Capitalization$1.14B
All Metrics
Book Value / Share (Quarterly)$4.51
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.70
Price vs S&P 500 (YTD)40.27%
EPS (TTM)$-0.79
10-Day Avg Trading Volume0.12M
EPS Excl Extra (TTM)$-0.79
EPS (Annual)$-0.79
ROI (Annual)-17.22%
Cash / Share (Quarterly)$4.53
ROA (Last FY)-16.74%
EBITD / Share (TTM)$-0.85
ROE (5Y Avg)-13.52%
Cash Flow / Share (Annual)$-0.70
P/B Ratio4.07x
P/B Ratio (Quarterly)2.82x
Net Income / Employee (Annual)$-1
ROA (TTM)-15.77%
EPS Incl Extra (Annual)$-0.79
Current Ratio (Annual)34.13x
Quick Ratio (Quarterly)34.13x
3-Month Avg Trading Volume0.31M
52-Week Price Return110.80%
Revenue / Employee (TTM)$0
52-Week High$19.51
EPS Excl Extra (Annual)$-0.79
26-Week Price Return45.67%
Quick Ratio (Annual)33.65x
13-Week Price Return8.46%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)34.13x
Enterprise Value$891.88
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.53
3-Month Return Std Dev64.08%
Net Income / Employee (TTM)$-1
ROE (Last FY)-17.25%
Net Interest Coverage (Annual)-17.89x
EPS Basic Excl Extra (Annual)$-0.79
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.79
ROI (TTM)-16.26%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)75.71%
Year-to-Date Return44.41%
5-Day Price Return12.24%
EPS Normalized (Annual)$-0.79
ROA (5Y Avg)-13.06%
Month-to-Date Return30.44%
EBITD / Share (Annual)$-0.85
ROI (5Y Avg)-13.48%
EPS Basic Excl Extra (TTM)$-0.79
P/B Ratio (Annual)2.82x
Book Value / Share (Annual)$4.51
Price vs S&P 500 (13W)5.59%
Beta1.19x
Revenue / Share (TTM)$0.00
ROE (TTM)-16.30%
52-Week Low$8.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GHRSGH Research PLC Ordinary Shares | — | — | — | — | $21.50 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
GH Research PLC is a clinical-stage biopharmaceutical company developing novel mebufotenin-based therapies for treatment-resistant depression. The company's pipeline includes two proprietary candidates: GH001, an inhalable formulation, and GH002, an intravenous formulation. GH Research is focused on addressing a significant unmet medical need in depression treatment through its dedicated R&D operations.